Identifying Red Flags and Patterns that Increase Cancer Risk (CME)

Original Release: April 24, 2014
Renewal Date: July 1, 2023
Expiration Date: June 30, 2026

Learning Objectives

• Analyze family history to guide evaluation of cancer risk
• Identify red flags to help determine risk level

Target Audience
Practicing primary care providers as well as students and residents.

Accreditation

The University of Connecticut School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Connecticut School of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Conflict of Interest Policy
All faculty members participating in CME activities sponsored by the University of Connecticut School of Medicine are required to disclose to the program audience any actual or apparent conflict of interest related to the content of their presentations. Program planners have an obligation to resolve any actual conflicts of interest and share with the audience any safeguards put in place to prevent commercial bias from influencing the content. 

• Emily Edelman, MS, CGC – The Jackson Laboratory 
• Therese Ingram, MA – The Jackson Laboratory 
• Kalisi Logan, MS, CGC – The Jackson Laboratory 
• Kate Reed, MPH, ScM, CGC – The Jackson Laboratory 
• Linda Steinmark, MS, CGC – The Jackson Laboratory 
• Hayley Dunnack Yackel, PhD, RN, CMSRN, OCN – Hartford Healthcare Cancer Institute 
• Fatima Amir, MS, CGC  - Genome Medical

Disclosure Statement

The activity director, the co-activity director, planning committee, writers and reviewers for this educational event have no relevant financial relationship(s) with any ineligible companies that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation that needs to be disclosed. This educational event will not be discussing the off-labeled or investigational use of any product or device.

Actors are being used in this program and are presenting information that has been scripted for them. They were not involved with the educational content of this activity. 

Commercial Support

This CME activity has no commercial support associated with it.

References

American College of Obstetricians and Gynecologists. Committee Opinion No. 478: Family History as a Risk Assessment Tool. Obstetrics & Gynecology. 2011; 117(3):747-750. 

American College of Obstetricians and Gynecologists. Committee Opinion No. 793: Hereditary Cancer Syndromes and Risk Assessment. Obstetrics & Gynecology. 2019; 134(6):e143-e149. 

American College of Obstetricians and Gynecologists. Practice Bulletin No. 147: Lynch Syndrome. Obstetrics & Gynecology. 2014; 124(5):1042-1054. 

Berliner JL, Cummings SA, Boldt Burnett B, Ricker CN. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes—Practice resource of the National Society of Genetic Counselors. J Genet Couns. 2021; 30(2):342-360. 

Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2014; 17(1):70-87. 

Holter S, Hall MJ, Hampel H, et al. Risk assessment and genetic counseling for Lynch syndrome - Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. J Genet Couns. 2022;31(3):568-583.  

Lundy MG, Forman A, Valverde K, Kessler L. An Investigation of Genetic Counselors’ Testing Recommendations: Pedigree Analysis and the Use of Multiplex Breast Cancer Panel Testing. J Genet Counsel. 2014; 23(4):618-632. 

Owens DK, Davidson KW, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement [published correction appears in JAMA. 2019 Nov 12;322(18):1830]. JAMA. 2019;322(7):652-665. 

National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Detection, Prevention and Risk Reduction. (Requires free registration). 

Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69(3):184-210.